A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets
Phase 1
Completed
- Conditions
- Bladder Cancer
- Interventions
- Drug: APL-1202+APL-1501 ER Tablets 3+APL-1501 ER Tablets 2Drug: APL-1501 ER Tablets 3+APL-1202+APL-1501 ER Tablets 2
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Asieris Pharmaceuticals (AUS) Pty Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT04601766
- Locations
- 🇦🇺
Scientia clinical research, Randwick, New South Wales, Australia
© Copyright 2025. All Rights Reserved by MedPath